Sign in
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
Journal article   Open access  Peer reviewed

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Renato D Lopes, Gretchen Heizer, Ronald Aronson, Amit N Vora, Tyler Massaro, Roxana Mehran, Shaun G Goodman, Stephan Windecker, Harald Darius, Jia Li, …
The New England journal of medicine, Vol.380(16), pp.1509-1524
2019-04-18
PMID: 30883055

Abstract

Pyrazoles - therapeutic use Humans Middle Aged Male Vitamin K - antagonists & inhibitors Acute Coronary Syndrome - complications Aspirin - adverse effects Aged, 80 and over Female Aspirin - therapeutic use Drug Therapy, Combination Platelet Aggregation Inhibitors - therapeutic use Purinergic P2Y Receptor Antagonists - therapeutic use Pyrazoles - adverse effects Double-Blind Method Atrial Fibrillation - drug therapy Atrial Fibrillation - complications Anticoagulants - therapeutic use Anticoagulants - adverse effects Factor Xa Inhibitors - therapeutic use Factor Xa Inhibitors - adverse effects Acute Coronary Syndrome - therapy Aged Pyridones - therapeutic use Hemorrhage - chemically induced Percutaneous Coronary Intervention Pyridones - adverse effects
url
https://doi.org/10.1056/NEJMoa1817083View
Published (Version of record) Open

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Highly Cited Paper 
Collaboration types
Industry collaboration
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.94 Cardiac Arrhythmia
1.94.95 Atrial Fibrillation
Web Of Science research areas
Cardiac & Cardiovascular Systems
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details